SEC Investigates Valeant Again

Canada-based, US-managed drug firm Valeant Pharmaceuticals has confirmed it is under another investigation by the Securities and Exchange Commission (SEC), the latest in a string of inquiries into its business affairs.

The SEC issued a subpoena in the fourth quarter of 2015, requesting information about Valeant’s previous relationship with pharmacy chain Philidor. Valeant terminated its ties with the group last October after it was accused of using it to falsify sales and boost prices.

News of the SEC probe capped an eventful 24 hours in which Valeant cancelled its 2016 financial guidance, delayed its fourth-quarter earnings report, announced that CEO Michael Pearson would return to work after a two-month medical leave, said it would take the chairman’s role away from Pearson, and indicated that one of its key drugs was under threat from a competitor.

The SEC is also separately investigating whether Salix Pharmaceuticals, which Valeant acquired last year, misled investors about its inventory levels in 2014.

Other investigations are continuing, by the US Attorney’s offices for Massachusetts and the Southern District of New York, as well as the US Congress, over Valeant’s drug pricing strategy.

The mounting scandals have pushed the company’s shares down and bond-rating company Moody’s has put Valeant’s credit rating on review for a possible downgrade.

In addition, Valeant has been hit by the news that rival firm Allergan has asked the Food and Drug Administration (FDA) for permission to sell a generic version of Xifaxan, its irritable bowel disease treatment. The drug had nearly $1 billion in sales last year.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.